Miraculous escape for 32 passengers as moving bus catches fire

Bengaluru, Mar 28: A case has been registered against an Infosys employee in Bengaluru for a shocking social media post urging people to "go out and sneeze" and spread the highly contagious COVID-19 virus that has infected over 800 people across the country and claimed 19 lives.

"Let's join hands, go out and sneeze with open mouth in public. Spread the virus," the man wrote on Facebook.
"A case has been registered against the person. Further investigation on. Looking forward to get adequate support from your end during investigation," Sandeep Patil, Joint Commissioner of Police, Crime, Bengaluru city tweeted by tagging along a tweet by Infosys.
Taking congnisance of the post by its employee, the Infosys said the post was "against the code of conduct and its commitment to responsible social sharing".
"Infosys has completed its investigation on the social media post by one of its employees and we believe that this is not a case of mistaken identity," the company said in a statement on Twitter.
"The social media post by the employee is against Infosys' code of conduct and its commitment to responsible social sharing. Infosys has a zero tolerance policy towards such acts and has accordingly, terminated the services of the employee," the statement added.

Earlier this month, the IT firm had vacated one of its buildings in Bengaluru after an employee was suspected to be infected.

Mangaluru, Mar 29: The second day of a total clampdown by Dakshin Kannada district had no impact as panic-stricken people rushed to buy essential commodities in markets in the City on Sunday without caring for Social distance to be maintained.

Since the crowd swell within minutes the police were forced to order the shops forcibly as otherwise, it might have led to spread of dreaded killer Coronavirus COVID-19.

The rise in Covid-19 cases in Dakshina Kannada and the neighbouring Kasargod district had forced the district administration to declare on total bandh on Saturday and Sunday but in vain.

The United States of America has bought almost the entire world's supply of remdesivir, one of just two drugs proven to treat COVID-19. 

“President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19,” said the US health and human services secretary, Alex Azar. 

“To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people.”

The announcement implies that no other country in the world will be able to buy remdesivir for next three months at least.

The anti-viral drug patented by the US-based Gilead biotech firm is the only one approved by the European Medicines Agency (EMA) to treat patients with the novel coronavirus.

The Trump administration has already shown that it is prepared to outbid and outmanoeuvre all other countries to secure the medical supplies it needs for the US.

“They’ve got access to most of the drug supply [of remdesivir], so there’s nothing for Europe,” said Dr Andrew Hill, senior visiting research fellow at Liverpool University.

Remdesivir, the first drug approved by licensing authorities in the US to treat Covid-19, is made by Gilead and has been shown to help people recover faster from the disease. 

The first 140,000 doses, supplied to drug trials around the world, have been used up. The Trump administration has now bought more than 500,000 doses, which is all of Gilead’s production for July and 90% of August and September.